Active, not recruitingPhase 3NCT04562766
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Principia Biopharma, a Sanofi Company
- Intervention
- Rilzabrutinib(drug)
- Enrollment
- 232 enrolled
- Eligibility
- 10 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Southern California_Investigational Site Number 84024, Los Angeles, California, United States
- UCSF Benioff Children's Hospital San Francisco_Investigational Site Number 84020, San Francisco, California, United States
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center_Investigational Site Number 84037, Torrance, California, United States
- The Oncology Institute of Hope and Innovation_Investigational Site Number 84031, Whittier, California, United States
- Children's Hospital Colorado_Investigational Site Number 84025, Aurora, Colorado, United States
- IMMUNOe International Research Centers_Investigational Site Number 84028, Centennial, Colorado, United States
- ASCLEPES Research Centers_Investigational Site Number 84023, Weeki Wachee, Florida, United States
- Children's Healthcare of Atlanta_Investigational Site Number 84034, Atlanta, Georgia, United States
- Rush University Medical Center_Investigational Site Number 84029, Chicago, Illinois, United States
- University of Louisville - James Graham Brown Cancer Center_Investigational Site Number 84033, Louisville, Kentucky, United States
- Massachusetts General Hospital Site Number : 84038, Boston, Massachusetts, United States
- Montefiore Medical Center_Investigational Site Number 84032, The Bronx, New York, United States
- University Hospitals Cleveland Medical Center Site Number : 84036, Cleveland, Ohio, United States
- Cleveland Clinic_Investigational Site Number 84026, Cleveland, Ohio, United States
- The Children's Hospital of Philadelphia (CHOP)_Investigational Site Number 84027, Philadelphia, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04562766 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation